Iscaff Pharma Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Iscaff Pharma General Information
Description
Developer of a biotechnology platform designed to focus on developing treatments for aggressive cancers. The company's platform provides cost-effective technology to enhance the success of clinical development of treatments for cancer, it provides technology for cancer diagnosis, prognosis, and testing of cancer drugs, enabling doctors to get a possible treatment for cancer.
Contact Information
Website
www.iscaffpharma.comCorporate Office
- Erik Dahlbergsgatan 11A
- 411 26 Gothenburg
- Sweden
Corporate Office
- Erik Dahlbergsgatan 11A
- 411 26 Gothenburg
- Sweden
Iscaff Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Dec-2025 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC | 01-Jan-2022 | Completed | Startup | |||
| 3. Early Stage VC | 01-Jan-2021 | Completed | Startup | |||
| 2. Early Stage VC | 01-Jan-2019 | $88.6K | $88.6K | Completed | Startup | |
| 1. Accelerator/Incubator | 01-Jun-2017 | Completed | Startup |
Iscaff Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 4,000 | $21.95 | $21.95 | 1x | $21.95 | 5.6% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Iscaff Pharma Patents
Iscaff Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4351669-A1 | Bioink for reproducible production of 3d tumor tissue scaffolds | Inactive | 10-Jun-2021 | ||
| US-20250122468-A1 | Bioink for reproducible production of 3d tumor tissue scaffolds | Pending | 10-Jun-2021 | ||
| WO-2022260583-A1 | Bioink for reproducible production of 3d tumor tissue scaffolds | Inactive | 10-Jun-2021 | ||
| EP-4103697-A1 | Uses of patient-derived scaffolds | Inactive | 03-Nov-2020 | ||
| EP-4103697-A4 | Uses of patient-derived scaffolds | Inactive | 03-Nov-2020 | C12N5/0693 |
Iscaff Pharma Signals
Iscaff Pharma Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Life Science Invest | Angel Group | Minority |
Iscaff Pharma FAQs
-
When was Iscaff Pharma founded?
Iscaff Pharma was founded in 2017.
-
Where is Iscaff Pharma headquartered?
Iscaff Pharma is headquartered in Gothenburg, Sweden.
-
What is the size of Iscaff Pharma?
Iscaff Pharma has 6 total employees.
-
What industry is Iscaff Pharma in?
Iscaff Pharma’s primary industry is Drug Discovery.
-
Is Iscaff Pharma a private or public company?
Iscaff Pharma is a Private company.
-
What is Iscaff Pharma’s current revenue?
The current revenue for Iscaff Pharma is .
-
How much funding has Iscaff Pharma raised over time?
Iscaff Pharma has raised $1.29M.
-
Who are Iscaff Pharma’s investors?
Life Science Invest has invested in Iscaff Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process